Namodenoson Phase 2a Pancreatic Cancer Study Enrollment Completed: Safety Endpoint Met, Top-Line Efficacy Data Expected in Q3 2026.

Can-Fite BioPharma has completed patient enrollment in its Phase 2a pancreatic cancer trial of Namodenoson. The drug has demonstrated a favorable safety profile and top-line efficacy data is expected in Q3 2026. Namodenoson is a highly selective A3 adenosine receptor agonist with potential anti-tumor activity in preclinical models. It has received Orphan Drug Designation from the FDA for the treatment of pancreatic cancer.